October 20, 2026 08:16 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Operation completed’: Tiger Shroff shooters allegedly alerted handlers after firing, probe reveals | 'I don't mind saying sorry 1,000 times': Sonu Nigam apologises to Kannadigas over ‘Pahalgam’ remark amid concert ban demand | After Vijay, is Dhanush eyeing politics? TVK calls Thalapathy an inspiration | Trump Says Paris Will Become ‘Muslim City Very Soon’, Blames Macron’s Immigration Policies | Four killed in fresh Manipur violence as protesters take bodies to Chief Minister’s residence | Tiger Shroff firing: Three accused arrested on train in Rajasthan, suspected Bishnoi gang link emerges | 'Internet access a fundamental right for children': SC rejects age-based 'blanket' ban | 'We will fight our own government': RG Kar victim's father threatens fresh protest after Sandip Ghosh gets bail | RG Kar shocker: Sandip Ghosh gets bail as only 7 of 147 witnesses examined, junior doctor blasts CBI | Trump waives Russia-related sanctions
Corona Remedies
Corona Remedies listed at 38% premium. Photo: ChatGPT

Corona Remedies storms Dalal Street! Shares list at 38% premium on debut

| @indiablooms | Dec 15, 2025, at 11:19 am

Mumbai/IBNS: Pharmaceutical firm Corona Remedies made a strong debut on the stock market on Monday, listing at a 38% premium over its IPO price on the National Stock Exchange (NSE), media reports said.

The company’s shares were listed at ₹1,470 apiece on the NSE, marking a 38.42% premium over the issue price.

On the BSE, the stock debuted at ₹1,452 per share, a 36.72% premium.

The ₹655.37-crore IPO, which was entirely an offer for sale, had a price band of ₹1,008–1,062 per share and was open for subscription from December 8 to 10.

Headquartered in Ahmedabad, Gujarat, Corona Remedies is an Indian pharmaceutical company with a strong presence in branded generics, catering to both chronic and acute therapy segments.

The robust listing underscored strong investor confidence in the company’s growth outlook and financial performance, reflecting sustained demand for quality pharma IPOs in the Indian market.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.